Richard W. Peck

Suggest Changes
Learn More
AIMS Zolmitriptan (311C90), a novel, selective, centrally and peripherally acting 5-HT1D-receptor agonist is under development as an acute treatment for migraine. The tolerability, pharmacokinetics(More)
BACKGROUND Older patients are potentially at risk from the effects of polypharmacy (PP) and/or drug-drug interactions. AIMS To examine the effects of a targeted patient-specific prescriber feedback(More)
1. The bioavailability and disposition of 882C87, an anti-varicella zoster virus (VZV) agent, have been investigated in healthy young and elderly volunteers. 2. The mean bioavailability of a 200 mg(More)